Report: Bausch & Lomb nears deal to sell itself to Valeant for $9B

May 24, 2013 at 2:55 PM

ROCHESTER, N.Y., May 24 (UPI) -- Bausch & Lomb Inc. is nearing a deal to be sold to Valeant Pharmaceuticals International Inc. for about $9 billion, The Wall Street Journal reported Friday.

Citing people familiar with the situation, the newspaper said Bausch & Lomb -- based in Rochester, N.Y., and owned by private-equity firm Warburg Pincus LLC -- could reach a deal with generic drug maker Valeant by next week.

One source cautioned the deal hasn't been finalized and could still collapse.

If the sale falls through, Warburg and Bausch & Lomb could go ahead with a planned initial public offering of stock in the eye-care company, the Journal said.

Like Us on Facebook for more stories from UPI.com  
Latest Headlines
Top Stories
Finland orders anti-tank weapon from Saab
Orbital ATK's artillery guidance kit passes milestone test
Fourth MUOS arrives in Florida for August launch
Oil prices drop on Greek, Iran concerns
North Dakota rig data suggests stability